Claims for Patent: 5,716,824

Summary for Patent: 5,716,824

Title:	2\'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
Abstract:	A compound having the formula: ##STR1## wherein, R1 represents 2\'-O-R.sub.3 -thio-R.sub.3 and/or 2\'-C-R.sub.3 -thio-R.sub.3, wherein R.sub.3 is independently a moiety selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester, X represents a base or H; Y represents a phosphorus-containing group; and R2 represents H, DMT or a phosphorus-containing group.
Inventor(s):	Beigelman; Leonid (Longmont, CO), Karpeisky; Alex (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/426,124
Patent Claims:	1. An enzymatic nucleic acid molecule comprising a modified nucleotide, wherein said modified nucleotide has the formula: ##STR3## wherein, R1 is independently 2'-O-R3-thio-R3 or 2'-C-R3-thio-R3, wherein said R3 is independently a compound selected from a group consisting of alkyl, allyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; X is independently a base or H; Y is independently a phosphorus-containing group; and R2 is independently a protecting group or a phosphorus-containing group. 2. The enzymatic nucleic acid of claim 1, wherein said protecting group is DMT. 3. The Enzymatic nucleic acid of claims 1 or 2 wherein said nucleic acid is in a hammerhead motif. 4. The Enzymatic nucleic acid of claims 1 or 2, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA or RNase P RNA motif. 5. The Enzymatic nucleic acid of claim 3, wherein position 4 of said hammerhead has the modified nucleotide, wherein said modified nucleotide is a 2'-O-methylthiomethyl nucleotide. 6. The Enzymatic nucleic acid of claim 3, wherein at least one of the positions in stem II region of said hammerhead has the modified nucleotide, wherein said modified nucleotide is a 2'-O-methylthiomethyl nucleotide. 7. The Enzymatic nucleic acid of claim 3, wherein at least one of the positions in said nucleic acid has the modified nucleotide, wherein said modified nucleotide is a 2'-O-methylthiophenyl nucleotide. 8. The Enzymatic nucleic acid of claim 3, wherein position 7 of said hammerhead has the modified nucleotide, wherein said modified nucleotide is a 2'-O-methylthiomethyl nucleotide. 9. The Enzymatic nucleic acid of claim 3, wherein positions 4 and 7 of said hammerhead have the modified nucleotide, wherein said modified nucleotide is a 2'-O-methylthiomethyl nucleotide. 10. The Enzymetic nucleic acid of claims 1 or 2, wherein said nucleic acid is in a hairpin configuration. 11. A mammalian cell in vitro comprising the enzymetic nucleic acid molecule of any one of the claims 1 or 2. 12. The in vitro mammalian cell of claim 11, wherein said cell is a human cell.

Details for Patent 5,716,824

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26